Siegfried to Acquire Early-Phase CDMO in USA

Business Strategy Siegfried to Acquire Early-Phase CDMO in USA

2024-06-27 Source: Press release Siegfried 1 min Reading Time

Related Vendor

Under binding agreements signed between Siegfried and Curia Global, Siegfried will acquire a CDMO specialized in early-phase development and manufacturing services in Grafton, Wisconsin. The new CDMO site is expected to strengthen Siegfried’s customer offering for Drug Substances.

Siegfried has signed binding agreements with Curia Global for the acquisition of an early-phase CDMO site in Grafton, Wisconsin, USA.(Source: Pixabay) — Siegfried has signed binding agreements with Curia Global for the acquisition of an early-phase CDMO site in Grafton, Wisconsin, USA.
(Source: Pixabay)

Zofingen/Switzerland – Siegfried, a leading global Contract Development and Manufacturing Organization (CDMO) for the pharmaceutical industry headquartered in Zofingen (Switzerland), has signed binding agreements with Curia Global for the acquisition of an early-phase CDMO site in Grafton, Wisconsin (US).

The new site, which specializes in early-phase development and manufacturing services with an experienced team of more than 80 employees, is set to strengthen Siegfried’s customer offering for Drug Substances in terms of capabilities and geographical coverage. Siegfried intends to develop the site into a best-in-class hub for early-phase CDMO services for its global customer base, including services for projects with highly potent APIs. Subject to customary closing conditions, the transaction is expected to close by July 1, 2024.

Reto Suter, CEO ad interim and CFO of Siegfried, commented: “With this acquisition, we enhance our offering with early-stage development services for Drug Substances and become even more relevant and attractive to our customers. Siegfried now offers an integrated range of services from early-stage development to commercial production of APIs through to the manufacturing of fully formulated Drug Products. This transaction will generate attractive opportunities and will further accelerate our growth story.”

The acquisition will strengthen Siegfried’s position in the United States, the world’s largest pharmaceutical market, and enables Siegfried to provide comprehensive support to customers in the pre-clinical and clinical development and manufacturing of Drug Substances. This further expands Siegfried’s offering, particularly for small and medium-sized pharmaceutical companies. The focus on early-phase CDMO services will further strengthen Siegfried’s Drug Substance pipeline by capturing additional attractive opportunities in their early stage, creating significant growth opportunities in the future.

The acquisition is financed from existing funds. The outlook for 2024 and the mid-term financial targets remains unchanged.

(ID:50078576)

Subscribe to the newsletter now

Don't Miss out on Our Best Content

Business E-mail

Please enter a valid mailadress.

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy. The consent declaration relates, among other things, to the sending of editorial newsletters by email and to data matching for marketing purposes with selected advertising partners (e.g., LinkedIn, Google, Meta)

Date: 08.12.2025

Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.

Consent to the use of data for promotional purposes

I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planck-Str. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here

Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.

Additionally, my consent also includes the processing of my email address and telephone number for data matching for marketing purposes with select advertising partners such as LinkedIn, Google, and Meta. For this, Vogel Communications Group may transmit said data in hashed form to the advertising partners who then use said data to determine whether I am also a member of the mentioned advertising partner portals. Vogel Communications Group uses this feature for the purposes of re-targeting (up-selling, cross-selling, and customer loyalty), generating so-called look-alike audiences for acquisition of new customers, and as basis for exclusion for on-going advertising campaigns. Further information can be found in section “data matching for marketing purposes”.

In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here. This does not apply to data matching for marketing purposes.

Right of revocation

I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://contact.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.